the serum ischemia modified albumin in patients with ankylosing spondylitis

Abstract

Background: Ankylosing spondylitis (AS) is a chronic, inflammatory disease that primarily affects the axial spine. Involvement of the sacroiliac joint is a hallmark of AS. AS is also associated with an increased risk of CVD (cardiovascular disease) which constitutes one of the main causes of death in these patients. AS is a complex immune-mediated condition whose pathogenesis is not fully understood. It is assumed that Reactive oxygen species is a major event in inflamed tissues leading to AS. Albumin acts as an antioxidant by removing oxidative stress products. Ischemia modified albumin (IMA) had gained wide acceptance as a systemic biomarker of oxidative stress. The aim of study to evaluate the serum level of ischemiamodified albumin in patients with ankylosing spondylitis and to correlate the ischemia-modified albumin serum level with disease activity indices, and carotid artery intima media thickness. Objective: The aim of the study was to evaluate the serum level of IMA in patients with AS and to correlate the IMA serum level with disease activity indices, and Carotid intima media thickness. Subjects and Methods: This cross-sectional study included 40 AS patients and 40 matched healthy controls. In AS patients, the activity parameters (BASDAI score, ASDAS-ESR, ASDAS-CRP, ESR and serum CRP levels) as well as BASFI score and BASMI score and treatment regimen were assessed. In addition, the cIMT and was measured for AS patients and controls. Ischemia-modified albumin (IMA) was also measured. Results: Patients with AS had significantly higher serum IMA level than controls. The ROC curve analysis revealed a strong ability of the IMA to discriminate the AS patients from controls. In AS patients, the serum IMA was significantly correlated with the cIMT and was higher in AS patients with plaques than those without plaques. Conclusion: our study has shown that the serum level of IMA was significantly higher in patients with AS than matched healthy controls. MA serum level was significantly correlated with AS activity and severity. Serum IMA can be used as a marker for subclinical atherosclerosis in AS.